- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00290706
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with bortezomib may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- Determine the response rate (complete and partial remission) in patients with relapsed or refractory aggressive B- or T-cell non-Hodgkin's lymphoma treated with gemcitabine hydrochloride and bortezomib.
- Determine the maximum tolerated dose of bortezomib when administered with gemcitabine hydrochloride in these patients.
Secondary
- Determine the time to treatment failure, duration of response, and overall survival of patients treated with this regimen.
- Determine the safety and tolerability of this regimen in these patients.
OUTLINE: This is a phase I, dose-escalation study of bortezomib followed by a phase II, open-label study.
- Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity (DLT) OR the dose that at which 2 of 6 patients experience DLT.
- Phase II: Patients receive gemcitabine hydrochloride and bortezomib as in phase I at the MTD.
After completion of study therapy, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Estados Unidos, 60611
- Veterans Affairs Medical Center - Lakeside Chicago
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL)
Intermediate histology B-cell NHL, including any of the following:
- Diffuse large B-cell lymphoma
- Transformed large cell lymphoma
- Any T-cell NHL histology
- Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed
- Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy
Must have received 1-3 prior therapeutic regimens
- Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered 1 regimen
- Monoclonal antibody (e.g., rituximab) given as maintenance therapy is considered 1 regimen
- Salvage chemotherapy followed by an autologous stem cell transplant is considered 1 regimen
- No more than 7 prior therapeutic regimens for patients with CTCL or MF
- No mantle cell lymphoma
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 3 months
- Absolute neutrophil count ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
- At least 50,000/mm^3 if documented bone marrow involvement
- Hemoglobin ≥ 8.0 g/dL
- AST and ALT ≤ 3 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 3 times ULN
- Bilirubin ≤ 2 times ULN
- Creatinine ≤ 2.0 mg/dL
- No known history of HIV infection
- No other active infection
- No uncontrolled hypertension
- No peripheral neuropathy ≥ grade 2 within the past 2 weeks
- No myocardial infarction within the past 6 months
- No New York Heart Association class III or IV heart failure
- No uncontrolled angina
- No severe uncontrolled ventricular arrhythmias
- No acute ischemia or active conduction system abnormalities by ECG
- No hypersensitivity to bortezomib, boron, or mannitol
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective barrier-method contraception
- No serious medical or psychiatric illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
- Prior autologous and/or allogeneic stem cell transplantation allowed
- More than 3 weeks since prior chemotherapy, radiotherapy, or immunotherapy
- More than 3 weeks since prior systemic biologic anticancer therapy
- More than 3 weeks since prior systemic corticosteroids (e.g., oral prednisone > 10 mg per day)
- More than 2 weeks since prior investigational drug
- No prior bortezomib or gemcitabine hydrochloride
- No other concurrent systemic cytotoxic chemotherapy or investigational agents
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Gemcitabine 800 mg/m2 + Bortezomib IVP over 3-5 seconds
Gemcitabine dose of 800 mg/m2 over 30 minutes followed by Bortezomib IVP given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
|
Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Outros nomes:
Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Response Rate in Patients With Relapsed or Refractory B- and T-cell NHL With Gemcitabine and Bortezomib Combination Treatment.
Prazo: At screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8
|
Response rate in patients with relapsed or refractory B- and T-cell NHL with Gemcitabine and Bortezomib combination treatment will be defined as the number of patients with Complete Remission [CR] and Partial Remission [PR]. CT scans at screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8 assessed by the Response Criteria for Non-hodgkins Lymphoma will be used to determine response where: CR=Complete disappearance of all detectable clinical and radiographic evidence of disease PR=> 50% decrease in SPD of the six largest dominant nodes or nodal masses |
At screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Time to Treatment Failure and Duration of Response
Prazo: At screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
Time to treatment failure and duration of response will be measured by CT Scan at screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
At screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
|
Overall Survival
Prazo: Every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Overall survival will be evaluated every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
|
Evaluate Safety and Tolerability of Bortezomib and Gemcitabine Therapy
Prazo: During treatment through a maximum of 8 Cycles (1 Cycle = 28 Days) and 30 days post last treatment
|
Safety and tolerability of the study drugs will be assessed on Day 1 and on either Day 8 or Day 15 of each treatment cycle (1 Cycle - 28 days) while on active treatment; and 30 days post last treatment. Adverse Events that are experienced by patients, determined to be either grade 3 or grade 4 and at least possibly related to at least one of the study drugs as assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0) will be collected. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE |
During treatment through a maximum of 8 Cycles (1 Cycle = 28 Days) and 30 days post last treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Leo Gordon, MD, Northwestern University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- linfoma folicular grau 3 recorrente
- linfoma difuso de grandes células adulto recorrente
- linfoma imunoblástico de grandes células do adulto recorrente
- linfoma difuso de células mistas do adulto recorrente
- linfoma linfoblástico adulto recorrente
- Linfoma não Hodgkin cutâneo recorrente de células T
- micose fungóide recorrente/síndrome de Sezary
Termos MeSH relevantes adicionais
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Linfoma
- Linfoma Não-Hodgkin
- Linfoma de Células T
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores Enzimáticos
- Antimetabólitos, Antineoplásicos
- Antimetabólitos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Gemcitabina
- Bortezomibe
Outros números de identificação do estudo
- NU 04H4 (Outro identificador: Northwestern University)
- VEL-03-082
- STU00007425 (Outro identificador: Northwestern University IRB)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em bortezomib
-
Virginia Commonwealth UniversityConcluídoMelanoma | Sarcoma de Partes Moles | Carcinoma de Paratireoide | Carcinoma de Pequenas Células do Pulmão | Tumores CarcinoidesEstados Unidos
-
University of ArkansasMillennium Pharmaceuticals, Inc.RescindidoMieloma múltiploEstados Unidos
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.ConcluídoCâncer de Cabeça e Pescoço | Neoplasias do Sistema Nervoso Central | Cancer cerebral | Câncer de colo do úteroEstados Unidos
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Millennium...ConcluídoLinfoma Linfoplasmocítico | Macroglobulinemia de WaldenstromEstados Unidos
-
Assistance Publique - Hôpitaux de ParisConcluídoEficácia do Bortezomib (Velcade(R)) em pacientes com macroglobulinemia de Waldenström avançada (WM2)Waldenstrom MacroglobulinemiaFrança
-
Mayo ClinicNational Cancer Institute (NCI)ConcluídoLeucemia | Distúrbios Mieloproliferativos CrônicosEstados Unidos
-
Millennium Pharmaceuticals, Inc.ConcluídoCarcinoma ColorretalEstados Unidos
-
The First Affiliated Hospital of Soochow UniversityDesconhecidoMieloma Múltiplo Comprovado por Exames LaboratoriaisChina
-
Columbia UniversityDesconhecidoMesoteliomaEstados Unidos